This site is intended for Healthcare Professionals only.

BioNTech, Pfizer to start testing pan-coronavirus shots

Date:

Share post:

BioNTech and Pfizer are to start tests on humans of next-generation vaccines that protect against a wide variety of coronaviruses in the second half of the year.

Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.

In presentation slides posted on BioNTech’s website for its investor day, the German biotech firm said its aim was to “provide durable variant protection”.

The two companies are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.

The virus’ persistent mutation into new variants that more easily evade vaccine protection, as well as waning human immune memory, have added urgency to the search by companies, governments and health bodies for more reliable tools of protection.

As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.

BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, which it acquired in October last year.

The Vienna-based antibiotics developer has done work on enzymes, made by bacteria-killing viruses, that break through the bacterial cell wall.

Drug-resistant infections are on the rise, driven by antibiotic overuse and leaks into the environment in antibiotics production.

Public health researchers put the combined number of people dying per year from antibiotic-resistant infections in the United States and the European Union at close to 70,000.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue December 2023

Related articles

Chelmsford drug dealer operating as ‘unlicensed chemist’ jailed for six years

Police discovered more than 50,000 pills and tablets of varying types at his residence on Wood Street in...

RPS and PDA respond to DHSC consultation on pharmacy supervision: Read here

Supervision by pharmacy technicians at hospital aseptic facilities should be considered in an entirely separate consultation, PDA said....

Over 100 medicines are currently in short supply, warns BGMA

Reducing disruptions to the movement of medicines around the world is “absolutely critical” for maintaining supply resilience in...

Dry cough syrup ‘codeine linctus’ reclassified to a prescription-only medicine

The drug regulator has warned that the use of codeine in recreational drinks can increase the risk of...